Therapeutic plasma exchange combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as ...

A first-of-its-kind clinical trial clinical trial shows that therapeutic plasma exchange (TPE) combined with intravenous ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.

Current treatment options include utilizing anticoagulation and intravenous immunoglobulin to inhibit antibody-mediated platelet activation, by blocking FcγRIIA (immunoglobulin gamma Fc region ...